---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-23-000014"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:08:13.863005+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Q1 revenue $506.9M (+10% YoY); Tyvaso sales up 39%

## Summary
- Net income $240.9M flat YoY; diluted EPS $4.86 vs $5.03.
- Tyvaso franchise net sales $238.4M (+39%) driven by Tyvaso DPI launch and label expansion.
- Treprostinil products grew 16% combined; Orenitram hit record revenue of $88.2M.
- R&D expense rose 20% to $82.9M, primarily on TETON IPF studies.
- Effective tax rate decreased to 17% from 22% due to excess share-based compensation benefits.

## SEC filing metadata
- accession: 0001082554-23-000014
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000014/0001082554-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000014/uthr-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-23-000014
- JSON: https://secwatch.observer/filing/0001082554-23-000014.json
- Plain text: https://secwatch.observer/filing/0001082554-23-000014.txt

## Key facts
- Earnings Releases
  UNITED THERAPEUTICS Corp reported quarter ended March 31, 2023 results: revenue $506.9 million, net income $240.9 million, EPS $4.86 per diluted share.
  - Period: quarter ended March 31, 2023
  - Revenue: $506.9 million
  - Net income: $240.9 million
  - EPS: $4.86 per diluted share
  - Result: reported results
  source text: Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000014/0001082554-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.